JP2009513713A5 - - Google Patents

Download PDF

Info

Publication number
JP2009513713A5
JP2009513713A5 JP2008538997A JP2008538997A JP2009513713A5 JP 2009513713 A5 JP2009513713 A5 JP 2009513713A5 JP 2008538997 A JP2008538997 A JP 2008538997A JP 2008538997 A JP2008538997 A JP 2008538997A JP 2009513713 A5 JP2009513713 A5 JP 2009513713A5
Authority
JP
Japan
Prior art keywords
inhibitor compound
composition
group
composition according
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008538997A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009513713A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/042653 external-priority patent/WO2007053685A2/en
Publication of JP2009513713A publication Critical patent/JP2009513713A/ja
Publication of JP2009513713A5 publication Critical patent/JP2009513713A5/ja
Pending legal-status Critical Current

Links

JP2008538997A 2005-11-01 2006-11-01 p38阻害剤化合物による心房細動の治療方法 Pending JP2009513713A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73267605P 2005-11-01 2005-11-01
PCT/US2006/042653 WO2007053685A2 (en) 2005-11-01 2006-11-01 Methods of treating atrial fibrillation with p38 inhibitor compounds

Publications (2)

Publication Number Publication Date
JP2009513713A JP2009513713A (ja) 2009-04-02
JP2009513713A5 true JP2009513713A5 (enExample) 2009-10-15

Family

ID=38006459

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008538997A Pending JP2009513713A (ja) 2005-11-01 2006-11-01 p38阻害剤化合物による心房細動の治療方法

Country Status (5)

Country Link
US (2) US20100029578A1 (enExample)
EP (1) EP1948178A4 (enExample)
JP (1) JP2009513713A (enExample)
CA (1) CA2627547A1 (enExample)
WO (2) WO2007053610A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0608907A2 (pt) 2005-05-10 2010-02-17 Itermune Inc método de modulação de sistema de proteìna cinase ativada por estresse
EP2296653B1 (en) 2008-06-03 2016-01-27 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US20110313004A1 (en) 2008-12-04 2011-12-22 Concert Pharmaceuticals, Inc. Deuterated pyridinones
WO2010085805A1 (en) * 2009-01-26 2010-07-29 Intermune, Inc. Methods for treating acute myocardial infarctions and associated disorders
EP2436670B1 (en) 2009-05-25 2014-04-16 Central South University Preparation of 1-(substituted aryl)-5-trifluoromethyl-2-(1H)pyridone compounds and salts thereof and their applications
CN102149683B (zh) 2009-05-25 2013-10-02 中南大学 1-(取代苄基)-5-三氟甲基-2-(1h)吡啶酮化合物及其盐,其制备方法及其用途
JP2013513086A (ja) * 2009-09-18 2013-04-18 アスチュート メディカル,インコーポレイテッド 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
TWI508726B (zh) 2009-12-21 2015-11-21 Gilead Sciences Inc 治療心房纖維性顫動之方法
US10105356B2 (en) 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
US10092552B2 (en) 2011-01-31 2018-10-09 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
CN102846555B (zh) * 2012-04-09 2014-06-25 珠海亿邦制药股份有限公司 一种以吡非尼酮为活性成分的固体制剂及其应用
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
EP4491180A1 (en) 2014-01-10 2025-01-15 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
RU2692485C2 (ru) 2014-04-02 2019-06-25 Интермьюн, Инк. Противофиброзные пиридиноны
EP3176164B1 (en) 2014-07-30 2019-08-21 Aetas Pharma Co. Ltd. Optical isomer of 1,4-benzothiazepine-1-oxide derivative, and pharmaceutical composition prepared using same
US10515284B2 (en) * 2014-09-30 2019-12-24 Qualcomm Incorporated Single-processor computer vision hardware control and application execution
EP3237385B1 (en) 2014-12-22 2021-11-24 The United States of America, as represented by The Secretary, Department of Health and Human Services Mutant idh1 inhibitors useful for treating cancer
CN105878243B (zh) * 2016-06-14 2019-05-21 四川大学 吡非尼酮衍生物在制药中的应用
CN105998018B (zh) * 2016-06-16 2019-01-25 杨若一 吡非尼酮衍生物在制药中的应用
CN107556234A (zh) * 2016-06-30 2018-01-09 陕西合成药业股份有限公司 一种新型吡啶酮类化合物及其制备方法和在医学上的应用
EP3569249A4 (en) * 2016-12-27 2020-11-11 Osaka University PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF REFRACTORY HEART DISEASE

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1049411A (en) * 1972-12-18 1979-02-27 Affiliated Medical Research N-substituted pyridone and general method for preparing pyridones
US4042699A (en) * 1972-12-18 1977-08-16 Affiliated Medical Research, Inc. Method for reducing serum glucose levels
US4052509A (en) * 1972-12-18 1977-10-04 Affiliated Medical Research, Inc. Method for reducing serum uric acid levels
US3839346A (en) * 1972-12-18 1974-10-01 Affiliated Med Res N-substituted pyridone and general method for preparing pyridones
PT590455E (pt) * 1992-09-28 2001-04-30 Hoechst Ag 1(2h)-isoquinolinas substituidas anti-arritmicas e cardioprotectoras processo para a sua preparacao medicamento contendo estes compostos e sua utilizacao para a preparacao de um medicamento para o combate de falhas cardiacas
JP2004523479A (ja) * 2000-10-18 2004-08-05 マサチューセッツ インスティテュート オブ テクノロジー 多糖の肺送達に関する方法および産物
US7030141B2 (en) * 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
US20040110710A1 (en) * 2002-08-23 2004-06-10 Xinkang Wang Methods of reducing ischemic injury
WO2004019863A2 (en) * 2002-08-28 2004-03-11 Intermune, Inc. Combination therapy for treatment of fibrotic disorders
WO2005040758A2 (en) * 2003-10-24 2005-05-06 Intermune, Inc. Use of pirfenidone in therapeutic regimens
US7550487B2 (en) * 2004-03-26 2009-06-23 Hoffmann-La Roche Inc. Pyrrolidine-3,4-dicarboxamide derivatives

Similar Documents

Publication Publication Date Title
JP2009513713A5 (enExample)
JP2021059610A (ja) 処置法
JP2015528471A5 (enExample)
JP2018514534A5 (enExample)
WO2013064900A1 (en) Oral immediate release formulations for substituted quinazolinones
EA020193B1 (ru) Комбинации, включающие метотрексат и ингибиторы дигидрооротатдегидрогеназы (dhodh)
AU2007271186C1 (en) Combination of HMG-CoA reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases
US20230364044A1 (en) Methods of Treating or Preventing Acute Respiratory Distress Syndrome
US10363235B2 (en) Compositions comprising 15-HEPE and methods of treating or preventing fibrosis using same
JP2024019691A (ja) 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法
JP2017513824A5 (enExample)
JP2006518731A5 (enExample)
US20060004076A1 (en) Co-administration of dehydroepiandrosterone (DHEA) congener with pharmaceutically active agents for treating inflammation
JP5084736B2 (ja) 肺高血圧を処置するためのジアリールウレア
JP2016512234A (ja) 薬学的複合製剤
TW201219037A (en) Prophylactic and/or therapeutic agent against lymphedema
JP2006514063A5 (enExample)
JP2009532494A5 (enExample)
WO2006104086A1 (ja) 血栓症治療剤
JP2008535907A5 (enExample)
CN104394865A (zh) 稳定性提高的并包含氨氯地平和氯沙坦的复合组合物
JPH0564124B2 (enExample)
JPH10175852A5 (enExample)
JP2019001830A (ja) 医薬
TW201206430A (en) Association of xanthine oxidase inhibitors and statins and use thereof